Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

(2023) Talha Munir et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

(2023) Peter Hillmen et al.   LANCET ONCOLOGY

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY

(2023) Paolo Ghia et al.   HemaSphere

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase 3 iLLUMINATE trial

(2022) Carol Moreno et al.   HAEMATOLOGICA

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

(2022) Constantine S. Tam et al.   BLOOD

Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial

(2022) Tait D. Shanafelt et al.   BLOOD

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

(2022) Arnon P Kater et al.   LANCET ONCOLOGY

Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia

(2022) Paul M. Barr et al.   Blood Advances

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

(2022) Mark-David Levin et al.   BLOOD

COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia

(2022) Mazyar Shadman et al.   HemaSphere

Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia

(2021) Isabelle G. Solman et al.   LEUKEMIA RESEARCH

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication

(2021) Pin Lu et al.   Blood Cancer Journal

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model for chronic lymphocytic leukemia

(2021) Arnon P. Kater et al.   Blood Advances

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

(2021) Othman Al-Sawaf et al.   JOURNAL OF CLINICAL ONCOLOGY

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

(2020) Jeff P Sharman et al.   LANCET

Obinutuzumab‐related adverse events: A systematic review and meta‐analysis

(2020) Irina Amitai et al.   HEMATOLOGICAL ONCOLOGY

Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies

(2020) Pronamee Borah et al.   BLOOD CELLS MOLECULES AND DISEASES

Ibrutinib and Venetoclax for First-Line Treatment of CLL

(2019) Nitin Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

(2019) Peter Hillmen et al.   JOURNAL OF CLINICAL ONCOLOGY

Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

(2019) Talha Munir et al.   AMERICAN JOURNAL OF HEMATOLOGY

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

(2018) Michael Hallek et al.   BLOOD

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

(2018) Jennifer A. Woyach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE